Terminated PHASE1 INTERVENTIONAL 1-arm NCT00985530

Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia

A Phase I Trial of Tamibarotene and Arsenic Trioxide for the Treatment of Relapsed Acute Promyelocytic Leukemia

Sponsor: Cephalon

Interventions Arsenic trioxide Tamibarotene

Updated 6 times since 2017 Last updated: Oct 28, 2013 Started: Oct 31, 2009 Primary completion: May 31, 2011 Completion: May 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Supporting agency withdrew funding for study.

Other terminated trials from Cephalon

See all terminations from Cephalon

This PHASE1 trial investigates Acute Promyelocytic Leukemia and is currently terminated or withdrawn. Cephalon leads this study, which shows 6 recorded versions since 2009 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Terminated PHASE1

First recorded

Oct 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cephalon
CytRx
Northwestern University

Data source: Northwestern University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chicago, United States